Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
largest decrease » marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
Showing 1,541 - 1,560 results of 13,040 for search '(( significant ((larger decrease) OR (largest decrease)) ) OR ( significant increase decrease ))', query time: 0.33s Refine Results
  1. 1541
  2. 1542

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  3. 1543

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  4. 1544

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  5. 1545
  6. 1546
  7. 1547
  8. 1548
  9. 1549
  10. 1550
  11. 1551
  12. 1552
  13. 1553
  14. 1554
  15. 1555
  16. 1556
  17. 1557
  18. 1558
  19. 1559
  20. 1560